A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C

被引:72
|
作者
Fong, TL
Han, SH
Tsai, NCS
Morgan, TR
Mizokami, M
Qian, DJ
Phan, C
Goad, K
Redeker, AG
机构
[1] Univ So Calif, Sch Med, Liver Unit, Los Angeles, CA USA
[2] Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
[3] St Francis Med Ctr, Honolulu, HI USA
[4] Vet Adm Med Ctr, Div Gastroenterol, Long Beach, CA 90822 USA
[5] Nagoya City Univ, Sch Med, Dept Med 2, Nagoya, Aichi 467, Japan
关键词
aminotransferase; phlebotomy;
D O I
10.1016/S0168-8278(98)80308-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Some studies have suggested that hepatic iron may influence the response to interferon therapy in chronic hepatitis C patients, We conducted this randomized, controlled trial to evaluate the effect of iron depletion on: (1) aminotransferase activity and hepatitis C RNA levels; and (2) response to interferon therapy in 38 patients with elevated alanine aminotransferase levels and who were HCV RNA positive, Methods: Seventeen patients underwent a 500-ml phlehotomy every 2 weeks until iron deficiency was achieved, Patients mere then started on a 6-month course of alpha-interferon 2b (3 mu tiw). Controls were 21 patients who were monitored for a 6- to 8-week period without phlebotomy prior to interferon therapy, Response to interferon was defined as loss of serum HCV RNA by reverse transcriptase-polymerase chain reaction, Serum HCV RNA was quantitated by bDNA technique, Results: Alanine aminotransferase levels decreased in 15/17 patients after phlebotomy, Mean alanine aminotransferase fell from 156.8 to 89.7 U/l (p=0.008), Changes in iron indices and alanine aminotransferase after phlebotomy were not accompanied by changes in HCV RNA levels, In control patients, neither alanine aminotransferase nor HCV RNA levels changed during the observation period, At the end of 24 weeks of interferon therapy 7/17 phlebotomized patients had a response, compared to 6/21 control patients (p=ns), After 6 months of follow-up, 5/17 phlebotomized patients remained HCV RNA negative, in contrast to only 1/21 controls (p=0.07). Conclusions: Iron depletion led to a reduction in aminotransferase levels; this was not accompanied by changes in levels of hepatitis C RNA, There may be an improvement in the sustained response to interferon therapy but this requires confirmation.
引用
收藏
页码:369 / 374
页数:6
相关论文
共 50 条
  • [21] Long-term outcome of chronic hepatitis C treated with interferon
    Hadziyannis, SJ
    Papatheodoridis, GV
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 31 (06): : 459 - 461
  • [22] PREDICTION OF LONG-TERM RESPONSE TO INTERFERON IN CHRONIC HEPATITIS-C - A FRACTAL APPROACH
    BOCCIA, S
    GAMBERINI, S
    DELLALIBERA, M
    MARIGNETTI, N
    LEROSE, R
    FORNACIARI, G
    GULLINI, S
    GASTROENTEROLOGY, 1995, 108 (04) : A1037 - A1037
  • [23] Long-term efficacy of interferon in chronic hepatitis C.
    Berg, T
    Kaul, T
    Heuft, HG
    Naumann, U
    Lobeck, H
    Hopf, U
    HEPATOLOGY, 1997, 26 (04) : 1178 - 1178
  • [24] Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C
    Vandelli, C
    Renzo, F
    Braun, HB
    Tisminetzky, S
    Albrecht, M
    De Palma, M
    Ranzi, A
    Di Marco, G
    Stroffolini, T
    Baralle, F
    Ventura, E
    Michel, G
    JOURNAL OF MEDICAL VIROLOGY, 1999, 58 (01) : 26 - 34
  • [25] Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: A randomized, controlled pilot study
    Quarantini, Lucas C.
    Miranda-Scippa, Angela
    Schinoni, Maria Isabel
    Sampaio, Aline S.
    Santos-Jesus, Rogerio
    Bressan, Rodrigo A.
    Tatsch, Fernando
    de Oliveira, Irismar
    Parana, Raymundo
    CLINICAL NEUROPHARMACOLOGY, 2006, 29 (03) : 138 - 143
  • [26] Thymosin-α 1 plus interferon-α for naive patients with chronic hepatitis C:: results of a randomized controlled pilot trial
    Andreone, P
    Gramenzi, A
    Cursaro, C
    Felline, F
    Loggi, E
    D'Errico, A
    Spinosa, M
    Lorenzini, S
    Biselli, M
    Bernardi, M
    JOURNAL OF VIRAL HEPATITIS, 2004, 11 (01) : 69 - 73
  • [27] Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon
    Veldt, Bart J.
    Hansen, Bettina E.
    Ikeda, Kenji
    Verhey, Elke
    Suzuki, Hiroshi
    Schalm, Solko W.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2006, 41 (09) : 1087 - 1094
  • [28] A RANDOMIZED, CONTROLLED TRIAL OF WEEKLY ADMINISTRATION OF LYMPHOBLASTOID INTERFERON IN PATIENTS WITH CHRONIC HEPATITIS-C
    KAGAWA, T
    MORIZANE, T
    SAITO, H
    MIYAGUCHI, S
    TSUNEMATSU, S
    TADA, S
    GUEVARA, FM
    KUMAGAI, N
    TSUCHIMOTO, K
    WATANABE, T
    TSUCHIYA, M
    JOURNAL OF HEPATOLOGY, 1993, 17 (01) : 91 - 96
  • [29] Interferon/antioxidant combination therapy for chronic hepatitis C - a controlled pilot trial
    Look, MP
    Gerard, A
    Rao, GS
    Sudhop, T
    Fischer, HP
    Sauerbruch, T
    Spengler, U
    ANTIVIRAL RESEARCH, 1999, 43 (02) : 113 - 122
  • [30] CAN URSODEOXYCOLIC ACID (UDCA) IMPROVE EFFECT OF ALPHA-INTERFERON IN CHRONIC-C HEPATITIS - LONG-TERM RESULTS OF A RANDOMIZED TRIAL
    BOTTELLI, R
    ZAVAGLIA, C
    GELOSA, F
    MAGGI, G
    MINOLA, E
    LEANDRO, G
    IDEO, G
    GASTROENTEROLOGY, 1993, 104 (04) : A879 - A879